BCG Vaccines Sales Market size was valued at USD 101.30 Million in 2024 and the total Global BCG Vaccines Sales revenue is expected to grow by 4.2% from 2025 to 2032, reaching nearly USD 140.78 MillionBCG Vaccines Sales Market Overview:
BCG Vaccines Sales is commercial and public sector distribution and revenue creation from the vaccines of Bacillus Calmette–Guérin (BCG) vaccine, which are mainly used to prevent tuberculosis (TB) and treat non-muscle invasive bladder cancer (NMIBC). Market encompasses the government's vaccination programs, hospital utilization and manufacturing, regulatory approval, global procurement, and regional sales through international health organizations such as the WHO, UNICEF, and PAHO. Growth in BCG vaccine sales market is increasing due to global TB and bladder cancer cases, extended vaccination programs and innovations in the recombinant BCG strains and regional manufacturing. For example, WHO estimated more than 10.3 million new TB cases globally in 2024, promoting continuous demand for extended BCG vaccination coverage, while North America has seen an increase in the use of BCG in the treatment of bladder cancer due to the ongoing decrease of its aging population and alternative remedies. Growth in technological progress such as VPM1002 such as rebuilding BCG strains and regional manufacturing hubs further intensified the expansion of the market. Asia-Pacific region led the market in 2024 due to high TB prevalence, strong local manufacturing (eg, Serum Institute, Sinopharm) and strong public health programs. Key players of the BCG Vaccine Sales Market include Serum Institute of India, AJ Vaccines, Sinopharm, Merck & Co., and Bio-Manguinhos/Fiocruz, driven by their global scale, which pre-intensification and integration with public health systems. In the BCG vaccine sales market, more than 65% of countries apply 0% tariffs to support public health, while the remaining typically impose low tariffs (1-5%). However, non-tariff barriers to which WHO prequalifications, customs obstacles, and cold chain certification, have increased. End users include national health ministries, global health organizations, hospitals, and cancer treatment centers that require safe, effective, and scalable vaccine solutions.To know about the Research Methodology :- Request Free Sample Report
Global BCG Vaccines Sales Market Dynamics
Increasing TB Prevalence and Early Immunization Drive BCG Vaccine Growth Bacillus Calmette–Guerin (BCG) vaccine is generally given to new born babies and up to six months old, but they can be vaccinated any time up to five years of age with a high incidence of TB. Tuberculosis is a severe infection, which damages the lungs and at times different parts of the body, for example, the joints, kidneys and bones. The BCG vaccine has existed for a long time and is a standout amongst the most broadly used of all conventional vaccines. The factors that drive the worldwide BCG vaccine market incorporate increment in the prevalence of tuberculosis, particularly in creating and undeveloped nations, and mechanical progression in the section of vaccine research. Nonetheless, symptoms of BCG vaccine and a worldwide lack of this vaccination hinder the development of the market.Global BCG Vaccines Sales Market Segmentation
Based on drug type, the immune BCG segment accounted for the highest share in 2023 and is also the fastest growing segment growing at a CAGR of 4.9% during the BCG vaccines sales market forecast period. The factors contributing toward the growth of this segment include the role of BCG in effectively helping TB prevention and as of now, there is no substitute vaccine for immune BCG. Based on Usage, the BCG Vaccines Sales Market is segmented into Tuberculosis and Bladder Cancer. Tuberculosis dominant segment in the BCG Vaccines Sales Market in 2024, accounting for the largest share due to its widespread use in national immunization programs, particularly in high TB-burden countries across Asia, Africa, and South America. The BCG vaccine has been a cornerstone of childhood TB prevention for decades, with the World Health Organization recommending it at birth in countries with high incidence. While BCG is increasingly used in treating non-muscle invasive bladder cancer (NMIBC), especially in developed regions, the volume and global reach of TB-related immunization far surpass oncology applications, making tuberculosis the leading usage category.
BCG Vaccines Sales Market Regional Insights:
From a geographical point of view, Asia-Pacific is expected to occupy more than two-thirds of the overall market shares by 2032, due to increased demand in low-level income population, i.e. India, to prevent tuberculosis epidemic. For now, the region of Latin America, the Middle East, and Africa (LAMEA) is predicted to grow at the highest CAGR of 5.3% due to increased awareness and higher disposable income of consumers. The BCG Vaccines Sales Market Report contains in-depth analysis of major drivers, opportunities, challenges and their impact on the market. The BCG Vaccines Sales Market report also provides data about the government policies. Also provides detail information of BCG Vaccines. This research report also adds a snapshot of key competition, market trends during the forecast period, expected growth rates and the primary factors driving and impacting growth market data. This information will be beneficial or helpful to the decision makers. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the Global BCG Vaccines Sales Market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global BCG Vaccines Sales Market. BCG Vaccines Sales Market: Competitive Landscape key players of BCG Vaccine Sales Market are Serum Institute of India, AJ Vaccines, Sinopharm, Merck & Co., and Bio-Manguinhos/Fiocruz, driven by their global scale, which pre-intensification and integration with public health systems. These companies are major global participants, reflecting industry-wide attention on extended vaccination coverage in both high-upper manufacturing, thermostable yogas, disease-specific BCG strains, and developing and developed fields. In addition, BB-NCIPD, BB-NCIPD, Biofabri, Butantan, IDT Biologika, and Haffkine are developing the target market through the development of BCG strands like BCG strands such as WHO-backed programs, regional vaccination participation, and VPM1002. The Serum Institute of India has reached an estimated USD 2.6 billion in 2024 revenue and maintains one of the largest global BCG capabilities, while Merck’s TICE BCG remains a major product for bladder cancer in North America despite recent deficiency. recombinant BCG strains such as technical promotion, WHO-backed procurement networks, and targeted regional production are re-shaping the competitive landscape, led by the global vaccine access with these firms. Key Trends in the BCG Vaccines Sales Market: • Dual-Use Expansion: TB & Bladder Cancer Growing use of BCG vaccines beyond tuberculosis, especially in non-muscle invasive bladder cancer (NMIBC), is expanding demand in high-income regions like North America and Europe. • Recombinant & Next-Gen BCG Development Advancements in recombinant BCG strains (e.g., VPM1002) are driving innovation, aiming for better safety, efficacy, and stability, especially for immunocompromised patients. • Global Supply Diversification & Local Manufacturing Increasing reliance on regional public manufacturers and tech transfer initiatives is improving access and reducing dependency on a few global suppliers, particularly in Africa and South America. Recent Developments in BCG Vaccines Sales Market:
Date Company Region Recent Development Apr 22, 2024 Serum Institute of India Pvt. Ltd. Asia-Pacific Partnered with ImmunityBio to supply BCG vaccines for FDA-approved Anktiva™ therapy in BCG-unresponsive bladder cancer. Feb 19, 2025 Intervax Ltd North America Announced scale-up of BCG vaccine production in partnership with WHO to meet rising demand from developing countries. Jan 10, 2025 Pfizer (via Biofabri collaboration) Europe Reported positive Phase III results combining sasanlimab with BCG for non-muscle invasive bladder cancer (NMIBC). Jun 06, 2024 Bio-Manguinhos/Fiocruz South America Expanded BCG manufacturing facility in Brazil with PAHO backing to increase regional vaccine self-sufficiency. Mar 15, 2025 BB-NCIPD Ltd Europe Signed MoU with African CDC to export BCG vaccine bulk material to new local fill-finish centers in Sub-Saharan Africa BCG Vaccines Sales Market Scope: Inquire before buying
BCG Vaccines Sales Market Report Coverage Details Base Year: 2024 Forecast Period: 2025-2032 Historical Data: 2019 to 2024 Market Size in 2024: USD 101.30 Mn. Forecast Period 2025 to 2032 CAGR: 4.2% Market Size in 2032: USD 140.78 Mn. Segments Covered: by Drug Type Immune BCG Therapy BCG by Usage Tuberculosis Bladder Cancer by End User Pediatrics Adults BCG Vaccines Sales Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America) North America: 1. Intervax Ltd (Canada) 2. Merck & Company Inc (USA) 3. Sanofi S.A. – Regional Facility (France) 4. Bio Farma (USA) 5. GreenSignal USA – Regional Partner (USA) 6. Pfizer Inc. (USA) Europe: 7. AJ Vaccines (Denmark) 8. Statens Serum Institute (Denmark) 9. BB-NCIPD Ltd. (Bulgaria) 10. Biofabri (Zendal Group) (Spain) 11. IDT Biologika (Germany) Asia-Pacific: 12. China National Pharmaceutical Group – Sinopharm (China) 13. Shanghai Institute of Biological Products (China) 14. Serum Institute of India Pvt. Ltd. (India) 15. Greensignal Bio Pharma Limited (India) 16. Haffkine Bio-Pharmaceutical Corporation Ltd. (India) South America 17. Bio-Manguinhos/Fiocruz (Brazil) 18. Instituto Butantan (Brazil) 19. ANLIS Malbrán (Argentina) 20. Sinergium Biotech (Argentina) 21. Instituto Nacional de Salud del Niño (Peru)Frequently Asked Questions:
1. Which region has the largest share in Global BCG Vaccines Sales Market? Ans: Asia-Pacific region held the highest share in 2024. 2. What is the growth rate of Global BCG Vaccines Sales Market? Ans: The Global Market is growing at a CAGR of 4.2% during forecasting period 2025-2032. 3. What is scope of the Global BCG Vaccines Sales market report? Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global BCG Vaccines Sales market? Ans: The BCG Vaccine Sales Market key player are Serum Institute of India, AJ Vaccines, Sinopharm, Merck & Co., and Bio-Manguinhos/Fiocruz. 5. What was the Global BCG Vaccines Sales Market size in 2024? Ans: The Global BCG Vaccines Sales Market size was USD 101.30 Million in 2024.
1. BCG Vaccines Sales Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. BCG Vaccines Sales Market: Competitive Landscape 2.1. Ecosystem Analysis 2.2. MMR Competition Matrix 2.3. Competitive Landscape 2.4. Key Players Benchmarking 2.4.1. Company Name 2.4.2. Business Segment 2.4.3. End-user Segment 2.4.4. Revenue (2024) 2.4.5. Company Locations 2.5. Market Structure 2.5.1. Market Leaders 2.5.2. Market Followers 2.5.3. Emerging Players 2.6. Mergers and Acquisitions Details 2.7. KANO Model Analysis 3. Global BCG Vaccines Sales Market: Dynamics 3.1. Region wise Trends of BCG Vaccines Sales Market 3.1.1. North America BCG Vaccines Sales Market Trends 3.1.2. Europe BCG Vaccines Sales Market Trends 3.1.3. Asia Pacific BCG Vaccines Sales Market Trends 3.1.4. Middle East and Africa BCG Vaccines Sales Market Trends 3.1.5. South America BCG Vaccines Sales Market Trends 3.2. BCG Vaccines Sales Market Dynamics 3.2.1. Global BCG Vaccines Sales Market Drivers 3.2.1.1. TB rise and infant immunization 3.2.1.2. Bladder cancer demand rises. 3.2.2. Global BCG Vaccines Sales Market Restraints 3.2.3. Global BCG Vaccines Sales Market Opportunities 3.2.3.1. TB surge in LMICs 3.2.3.2. Bladder cancer expansion 3.2.3.3. Global vaccine backing 3.2.4. Global BCG Vaccines Sales Market Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Using Tree-Map Analysis 3.4.1. TB vaccination mandates 3.4.2. Global health funding rises 3.4.3. BCG strain innovation 3.5. Regulatory Landscape by Region 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 4. BCG Vaccines Sales Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 4.1. BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 4.1.1. Immune BCG 4.1.2. Therapy BCG 4.2. BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 4.2.1. Tuberculosis 4.2.2. Bladder Cancer 4.3. BCG Vaccines Sales Market Size and Forecast, By End User (2024-2032) 4.3.1. Residential 4.3.2. Commercial 4.3.3. Hospitality 4.3.4. Retail Stores 4.4. BCG Vaccines Sales Market Size and Forecast, by Region (2024-2032) 4.4.1. North America 4.4.2. Europe 4.4.3. Asia Pacific 4.4.4. Middle East and Africa 4.4.5. South America 5. North America BCG Vaccines Sales Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 5.1. North America BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 5.1.1. Immune BCG 5.1.2. Therapy BCG 5.2. North America BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 5.2.1. Tuberculosis 5.2.2. Bladder Cancer 5.3. North America BCG Vaccines Sales Market Size and Forecast, By End User (2024-2032) 5.3.1. Pediatrics 5.3.2. Adults 5.4. North America BCG Vaccines Sales Market Size and Forecast, by Country (2024-2032) 5.4.1. United States 5.4.1.1. United States BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 5.4.1.1.1. Immune BCG 5.4.1.1.2. Therapy BCG 5.4.1.2. United States BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 5.4.1.2.1. Tuberculosis 5.4.1.2.2. Bladder Cancer 5.4.1.3. United States BCG Vaccines Sales Market Size and Forecast, By End User (2024-2032) 5.4.1.3.1. Pediatrics 5.4.1.3.2. Adults 5.4.2. Canada 5.4.2.1. Canada BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 5.4.2.1.1. Immune BCG 5.4.2.1.2. Therapy BCG 5.4.2.2. Canada BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 5.4.2.2.1. Tuberculosis 5.4.2.2.2. Bladder Cancer 5.4.2.3. Canada BCG Vaccines Sales Market Size and Forecast, By End User (2024-2032) 5.4.2.3.1. Pediatrics 5.4.2.3.2. Adults 5.4.3. Mexico 5.4.3.1. Mexico BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 5.4.3.1.1. Immune BCG 5.4.3.1.2. Therapy BCG 5.4.3.2. Mexico BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 5.4.3.2.1. Tuberculosis 5.4.3.2.2. Bladder Cancer 5.4.3.3. Mexico BCG Vaccines Sales Market Size and Forecast, By End User (2024-2032) 5.4.3.3.1. Pediatrics 5.4.3.3.2. Adults 6. Europe BCG Vaccines Sales Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 6.1. Europe BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 6.2. Europe BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 6.3. Europe BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 6.4. Europe BCG Vaccines Sales Market Size and Forecast, by Country (2024-2032) 6.4.1. United Kingdom 6.4.1.1. United Kingdom BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 6.4.1.2. United Kingdom BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 6.4.1.3. United Kingdom BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 6.4.2. France 6.4.2.1. France BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 6.4.2.2. France BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 6.4.2.3. France BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 6.4.3. Germany 6.4.3.1. Germany BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 6.4.3.2. Germany BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 6.4.3.3. Germany BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 6.4.4. Italy 6.4.4.1. Italy BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 6.4.4.2. Italy BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 6.4.4.3. Italy BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 6.4.5. Spain 6.4.5.1. Spain BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 6.4.5.2. Spain BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 6.4.5.3. Spain BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 6.4.6. Sweden 6.4.6.1. Sweden BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 6.4.6.2. Sweden BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 6.4.6.3. Sweden BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 6.4.7. Austria 6.4.7.1. Austria BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 6.4.7.2. Austria BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 6.4.7.3. Austria BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 6.4.8. Rest of Europe 6.4.8.1. Rest of Europe BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 6.4.8.2. Rest of Europe BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 6.4.8.3. Rest of Europe BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7. Asia Pacific BCG Vaccines Sales Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 7.1. Asia Pacific BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.2. Asia Pacific BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.3. Asia Pacific BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4. Asia Pacific BCG Vaccines Sales Market Size and Forecast, by Country (2024-2032) 7.4.1. China 7.4.1.1. China BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.1.2. China BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.1.3. China BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.2. S Korea 7.4.2.1. S Korea BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.2.2. S Korea BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.2.3. S Korea BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.3. Japan 7.4.3.1. Japan BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.3.2. Japan BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.3.3. Japan BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.4. India 7.4.4.1. India BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.4.2. India BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.4.3. India BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.5. Australia 7.4.5.1. Australia BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.5.2. Australia BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.5.3. Australia BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.6. Indonesia 7.4.6.1. Indonesia BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.6.2. Indonesia BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.6.3. Indonesia BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.7. Philippines 7.4.7.1. Philippines BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.7.2. Philippines BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.7.3. Philippines BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.8. Malaysia 7.4.8.1. Malaysia BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.8.2. Malaysia BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.8.3. Malaysia BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.9. Vietnam 7.4.9.1. Vietnam BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.9.2. Vietnam BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.9.3. Vietnam BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.10. Thailand 7.4.10.1. Thailand BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.10.2. Thailand BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.10.3. Thailand BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 7.4.11. Rest of Asia Pacific 7.4.11.1. Rest of Asia Pacific BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 7.4.11.2. Rest of Asia Pacific BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 7.4.11.3. Rest of Asia Pacific BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 8. Middle East and Africa BCG Vaccines Sales Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 8.1. Middle East and Africa BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 8.2. Middle East and Africa BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 8.3. Middle East and Africa BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 8.4. Middle East and Africa BCG Vaccines Sales Market Size and Forecast, by Country (2024-2032) 8.4.1. South Africa 8.4.1.1. South Africa BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 8.4.1.2. South Africa BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 8.4.1.3. South Africa BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 8.4.2. GCC 8.4.2.1. GCC BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 8.4.2.2. GCC BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 8.4.2.3. GCC BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 8.4.3. Nigeria 8.4.3.1. Nigeria BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 8.4.3.2. Nigeria BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 8.4.3.3. Nigeria BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 8.4.4. Rest of ME&A 8.4.4.1. Rest of ME&A BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 8.4.4.2. Rest of ME&A BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 8.4.4.3. Rest of ME&A BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 9. South America BCG Vaccines Sales Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 9.1. South America BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 9.2. South America BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 9.3. South America BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 9.4. South America BCG Vaccines Sales Market Size and Forecast, by Country (2024-2032) 9.4.1. Brazil 9.4.1.1. Brazil BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 9.4.1.2. Brazil BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 9.4.1.3. Brazil BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 9.4.2. Argentina 9.4.2.1. Argentina BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 9.4.2.2. Argentina BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 9.4.2.3. Argentina BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 9.4.3. Rest of South America 9.4.3.1. Rest of South America BCG Vaccines Sales Market Size and Forecast, By Drug Type (2024-2032) 9.4.3.2. Rest of South America BCG Vaccines Sales Market Size and Forecast, By Usage (2024-2032) 9.4.3.3. Rest of South America BCG Vaccines Sales Market Size and Forecast, End User (2024-2032) 10. Company Profile: Key Players (Detailed Profile for all Major Industry Players) 10.1. Pfizer Inc. (USA) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Recent Developments 10.2. Intervax Ltd (Canada) 10.3. Merck & Company Inc (USA) 10.4. Sanofi S.A. – Regional Facility (France) 10.5. Bio Farma (USA) 10.6. GreenSignal USA – Regional Partner (USA) 10.7. AJ Vaccines (Denmark) 10.8. Statens Serum Institute (Denmark) 10.9. BB-NCIPD Ltd. (Bulgaria) 10.10. Biofabri (Zendal Group) (Spain) 10.11. IDT Biologika (Germany) 10.12. China National Pharmaceutical Group – Sinopharm (China) 10.13. Shanghai Institute of Biological Products (China) 10.14. Serum Institute of India Pvt. Ltd. (India) 10.15. Greensignal Bio Pharma Limited (India) 10.16. Haffkine Bio-Pharmaceutical Corporation Ltd. (India) 10.17. Bio-Manguinhos/Fiocruz (Brazil) 10.18. Instituto Butantan (Brazil) 10.19. ANLIS Malbrán (Argentina) 10.20. Sinergium Biotech (Argentina) 10.21. Instituto Nacional de Salud del Niño (Peru) 11. Key Findings 12. Analyst Recommendations 13. BCG Vaccines Sales Market: Research Methodology
